A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients

References

• Myers MG, Lewis GR, Steiner J, et al. Atenolol in essential hypertension. Clin Pharmacol Ther 1976;19(5 Pt 1):502–07.
   PubMed Web of Science ®Google Scholar
• Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008;21(6):663–67.
   PubMed Web of Science ®Google Scholar
• Armentano RL, Graf S, Ramirez AJ, et al. Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients. Medicina (B Aires) 2001; 61(5 Pt 1):535–40.
   PubMed Web of Science ®Google Scholar
• Bhatt AB, Buck JS, Zuflacht JP, et al. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vasc Med 2015; 20(4):317–25.
   PubMed Web of Science ®Google Scholar
• Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press Suppl 2007;2:25–30.
   PubMedGoogle Scholar
• Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009;54(2):409–13.
   PubMed Web of Science ®Google Scholar
• Georgianos PI, Agarwal R. Effect of lisinopril and atenolol on aortic stiffness in patients on hemodialysis. Clin J Am Soc Nephrol 2015;10(4):639–45.
   PubMed Web of Science ®Google Scholar
• Asmar RG, London GM, O’Rourke ME, et al. Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. J Hypertens Suppl 2001;19(4):S15–20.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• Crowther M, Lim W, Crowther MA. Systematic review and meta-analysis methodology. Blood 2010;116(17):3140–46.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177–88.
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557–60.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56(2):455–63.
   PubMed Web of Science ®Google Scholar
• Savolainen A, Keto P, Poutanen VP, et al. Effects of angiotensin-converting enzyme inhibition versus [beta]-adrenergic blockade on aortic stiffness in essential hypertension. J Cardiovasc Pharmacol 1996;27(1):99.
   PubMed Web of Science ®Google Scholar
• Komai N, Ohishi M, Morishita R, et al. Serum hepatocyte growth factor concentration is correlated with the forearm vasodilator response in hypertensive patients. Am J Hypertens 2002;15(6):499–506.
   PubMed Web of Science ®Google Scholar
• London GM, Asmar RG, O’Rourke MF, et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004;43(1):92–9.
   PubMed Web of Science ®Google Scholar
• Koumaras C, Tziomalos K, Stavrinou E, et al. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens 2014;8(2):74–82.
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Athyros V, Papageorgiou A, et al. Should atenolol still be recommended as first-line therapy for primary hypertension? Hellenic J Cardiol 2006;47(5):298–307.
   PubMedGoogle Scholar
• Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100(8):1254–62.
   PubMed Web of Science ®Google Scholar
• Kuyper LM, Khan NA. Atenolol vs nonatenolol beta-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol 2014;30(5 Suppl):S47–53.
   PubMed Web of Science ®Google Scholar
• Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113(9):1213–25.
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995–1003.
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994;23(1):83–91.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F. Cardiovascular protection by beta-blockade in hypertensive haemodialysis patients: the Hypertension in Haemodialysis Patients Treated With Atenolol or Lisinopril (HDPAL) trial. Nephrol Dial Transplant 2014;29(3):483–85.
   PubMed Web of Science ®Google Scholar
• Neutel JM, Schnaper H, Cheung DG, et al. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J 1990;120(1):166–71.
   PubMed Web of Science ®Google Scholar